Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 10Leukemia, Myeloid, Acute 7Congenital Abnormalities 6Glioblastoma 5Lung Neoplasms 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Gliosarcoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Wilms Tumor 3Uterine Cervical Neoplasms 3Squamous Intraepithelial Lesions 3Myelodysplastic Syndromes 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Ovarian Neoplasms 2Oligodendroglioma 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Kidney Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Brain Neoplasms 2

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × DNA Methylation × Clear all
NCT01155583 2020-11-16

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1/2 Completed
45 enrolled 20 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡